BactiVax

BactiVax: Anti-Bacterial Innovative Vaccines

EU Horizon 2020 project: CORDIS (BactiVax)

BactiVax is an innovative European Training Network that provides high-level training in vaccinology to 15 high-achieving, creative Early Stage Researchers (ESRs), and equips them with a wide range of transferrable skills for thriving careers in vaccine research within academia and industry.

BactiVax focuses on developing novel vaccines to tackle the huge challenge of antimicrobial-resistant human pathogens that cause chronic, life-threatening respiratory and/or systemic infections. This network comprises 14 Principal Investigators with expertise in vaccinology, proteomics, medicine, microbiology, biochemistry, immunology, structural biology, medicinal, peptide and glycochemistry from 8 European countries and two companies, which collectively train ESRs in entrepreneurship, commercial vaccine development and bioprocessing.

Participant organisations

University College Dublin, National Research Council (Naples), Queen's University Belfast, CIC bioGUNE (Bilbao), St. George's University of London, Ludwig Maximilian University of Munich, University of Milano Bicocca, Imperial College London, École Polytechnique Fédérale de Lausanne, Eötvös Loránd University (Budapest), Lionex GmbH (Braunschweig), and ImmunXperts (Belgium).

Lionex: Prof. Mahavir Singh